NCT04358913 MR Imaging Study Using the Northern Alberta Linac-MR (Northern LIGHTs - 1)
| NCT ID | NCT04358913 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AHS Cancer Control Alberta |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2021-08-23 |
| Primary Completion | 2029-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2021-08-23 with a primary completion date of 2029-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cancers are often treated with external beam radiotherapy. Current radiotherapy treatments are performed using computed tomography (also known as CT) scans which may not always clearly identify the cancer. In some instances, magnetic resonance imaging (MRI) may be able to better identify cancers. Therefore, efforts are currently underway to use the MRI scans to improve radiotherapy treatments or eventually even use radiotherapy equipment that only uses MRI scans to guide treatments. This new technology that will only use MRI scans to guide treatments is called the Linac-MR (linear accelerator with an MRI). The purpose of this pilot phase of the study is to test whether the Alberta linac-MR P3 system at the Cross Cancer Institute can acquire high quality MR images safely. It will allow the researchers to develop the best collection of MR images possible with this new machine, in order to allow them to visualize tumors for future patients that are treated on this machine.
Eligibility Criteria
Inclusion Criteria: * Adults ≥ 18 years of age * Patients deemed fit to undergo high dose external beam radiation therapy by their attending radiation oncologist Exclusion Criteria: * Patients with contraindications for MRI * Patients who are unable to lie flat and still for the duration of the expected scan acquisition * Patients who are unable to provide informed consent
Contact & Investigator
Nawaid Usmani, MD
PRINCIPAL INVESTIGATOR
Cross Cancer Institute, Alberta Health Services
Frequently Asked Questions
Who can join the NCT04358913 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04358913 currently recruiting?
Yes, NCT04358913 is actively recruiting participants. Contact the research team at Nawaid.Usmani@ahs.ca for enrollment information.
Where is the NCT04358913 trial being conducted?
This trial is being conducted at Edmonton, Canada.
Who is sponsoring the NCT04358913 clinical trial?
NCT04358913 is sponsored by AHS Cancer Control Alberta. The principal investigator is Nawaid Usmani, MD at Cross Cancer Institute, Alberta Health Services. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.